ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Premium IconPremium Help Menu
S&P 500
5,976.97
-1.13%
US Tech 100
21,079.20
-1.25%
Dow Jones
42,197.79
-1.79%
Brent Oil
73.815
0.00%
Bitcoin
105,013.24
-1.06%
Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Altimmune Inc (ALT) Quote

Altimmune Inc

Altimmune Inc (ALT)

Analytica Limited
Altitude Group Plc
Alturas Minerals Corp
6.92
-0.23
(-3.22%)
Closed June 14 4:00PM
15 min delayed - Upgrade to Realtime
6.969
0.049
(0.71%)
After Hours: 7:34PM
15 min delayed - Upgrade to Realtime

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Key stats and details

Current Price
6.969
Bid
6.93
Ask
6.97
Volume
4,336,494
6.75 Day's Range 7.405
3.553 52 Week Range 11.16
Market Cap
565.234M
Previous Close
7.15
Open
6.94
Last Trade
6
@
6.96
Last Trade Time
Financial Volume
$ 30,613,600
VWAP
7.0595
Average Volume (3m)
2,511,861
Shares Outstanding
81,106,973
Dividend Yield
-
PE Ratio
-5.90
Earnings Per Share (EPS)
-1.17
Revenue
20k
Net Profit
-95.06M

About Altimmune Inc

Altimmune Inc is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the tre... Altimmune Inc is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH (non-alcoholic steatohepatitis). In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B virus (HBV). Show more

Sector
Blank Checks
Industry
Pharmaceutical Preparations
Website
www.altimmune.com
Headquarters
Wilmington, Delaware, USA
Founded
2005
Altimmune Inc is listed in the Blank Checks sector of the NASDAQ with ticker ALT. The last closing price for Altimmune was $7.15. Over the last year, Altimmune shares have traded in a share price range of $ 3.553 to $ 11.16.

Altimmune currently has 81,106,973 shares outstanding. The market capitalization of Altimmune is $579.91 million. Altimmune has a price to earnings ratio (PE ratio) of -5.90.

Ask ADVFN Intelligence (AI)

Altimmune (ALT) Options Flow Summary

ALT Options Flow

Overall Flow

Bullish

Net Premium

447k

Calls / Puts

400.00%

Buys / Sells

66.67%

OTM / ITM

100.00%

Sweeps Ratio

0.00%

ALT Latest News

More News

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Edgar (US Regulatory)
May 13 2025
ALT (-3.22%)

Form 8-K - Current report
Edgar (US Regulatory)
May 13 2025
ALT (-3.22%)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
11.48927.17153284675.487.485.4750059786.5584416CS
41.16920.15517241385.87.485.1529815725.98293664CS
121.31923.34513274345.657.483.55325118615.4255508CS
26-1.671-19.34027777788.649.593.55325643716.09804694CS
520.5799.061032863856.3911.163.55328396446.78517149CS
156-1.081-13.42857142868.0523.492.0931752397.91567736CS
260-0.381-5.183673469397.3535.12.0925771359.76964158CS

ALT - Frequently Asked Questions (FAQ)

What is the current Altimmune share price?
The current share price of Altimmune is $ 6.969
How many Altimmune shares are in issue?
Altimmune has 81,106,973 shares in issue
What is the market cap of Altimmune?
The market capitalisation of Altimmune is USD 579.91M
What is the 1 year trading range for Altimmune share price?
Altimmune has traded in the range of $ 3.553 to $ 11.16 during the past year
What is the PE ratio of Altimmune?
The price to earnings ratio of Altimmune is -5.9
What is the cash to sales ratio of Altimmune?
The cash to sales ratio of Altimmune is 34.55k
What is the reporting currency for Altimmune?
Altimmune reports financial results in USD
What is the latest annual turnover for Altimmune?
The latest annual turnover of Altimmune is USD 20k
What is the latest annual profit for Altimmune?
The latest annual profit of Altimmune is USD -95.06M
What is the registered address of Altimmune?
The registered address for Altimmune is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
What is the Altimmune website address?
The website address for Altimmune is www.altimmune.com
Which industry sector does Altimmune operate in?
Altimmune operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
RBNERobin Energy Ltd
$ 13.85
(313.43%)
101.81M
OPOceanPal Inc
$ 1.63
(125.45%)
80.28M
LGHLWLion Group Holding Ltd
$ 0.0052
(116.67%)
6.87M
NEONNeonode Inc
$ 16.83
(68.47%)
4.78M
ICONIcon Energy Corporation
$ 2.90
(62.01%)
59.04M
SBETSharpLink Gaming Inc
$ 9.2275
(-71.63%)
41.92M
AIHSSenmiao Technology Ltd
$ 0.381
(-63.01%)
16.8M
CHSNChanson International Holding
$ 0.22
(-60.00%)
15.15M
KWMK Wave Media Ltd
$ 2.91
(-50.43%)
2.59M
JZXNJiuzi Holdings Inc
$ 1.56
(-46.39%)
2.24M
HCTIHealthcare Triangle Inc
$ 0.0201
(-33.00%)
856.89M
GNLNGreenlane Holdings Inc
$ 0.0101
(-34.42%)
792.34M
CGBSCrown LNG Holdings Ltd
$ 0.1104
(31.43%)
788.42M
TSLLDirexion Daily TSLA Bull 2X Trust ETF
$ 12.655
(3.81%)
246.13M
NVDANVIDIA Corporation
$ 141.97
(-2.09%)
180.81M

ALT Discussion

View Posts
Monksdream Monksdream 2 months ago
ALT, new 52 week low
šŸ‘ļø0
Kam8 Kam8 3 months ago
Thank you so much for your kind reply.👍️👍️👍️
šŸ‘ļø0
akamaii akamaii 3 months ago
I think after mash data if itā€™s like last trials you can bet for a deal or buyout
👍 1 😍 1
Kam8 Kam8 3 months ago
BO soon???
šŸ‘ļø0
Monksdream Monksdream 3 months ago
ALT, new 52 week low
šŸ‘ļø0
Mark102 Mark102 6 months ago
Still Holding here
As far as buyout and the OS you're looking at roughly 7 billion = 100 a share
10 billion = 140

👍 1
Mark102 Mark102 10 months ago
As promised I don't see any dilution in the filing. Shorts are in trouble
👍 1
Mark102 Mark102 10 months ago
Float is Locked and over 23 million naked shares Short. Shorts have failed Miserably at shaking out Retail and can't cover without a massive loss.
Price Targets
Partner 50 to 75
Buyout 140 to 200
👍 1
Mark102 Mark102 11 months ago
https://forextv.com/top-news/altimmune-announces-publication-of-clinical-study-of-pemvidutide-in-metabolic-dysfunction-associated-steatotic-liver-disease-masld-in-journal-of-hepatology/
👍 1 💯 1
Mark102 Mark102 11 months ago
IT'S HAPPENING
šŸ‘ļø0
Mark102 Mark102 11 months ago
Beautiful Bull Flag
šŸ‘ļø0
girlfriend girlfriend 12 months ago
Well....not quite but a nice pop anyways this week.
šŸ‘ļø0
Mark102 Mark102 12 months ago
Last chance next week above 20
šŸ‘ļø0
Mark102 Mark102 12 months ago
It's being shorted by its competitors not tutes. . An advisor from Lilly is making the presentations of pemvi data this weekend.its what you know not what some want you to believe.
👍 1
brfv11 brfv11 1 year ago
Not a chance at 60. Shorts are playing this one perfectly. Investors are just not interested in ALT. Good luck.
👍 1
Mark102 Mark102 1 year ago
Shorts looking weak and vulnerable today any trading room with the funds could squeeze this to 60 easy
šŸ‘ļø0
Mark102 Mark102 1 year ago
Goldman Sachs been short stacking here for months and they are hosting the fireside tomorrow. I'm loading up today
šŸ‘ļø0
brfv11 brfv11 1 year ago
Time to admit shorty got this one right! This one is going all the way down.
Merger/ buyout what a joke.
šŸ‘ļø0
akamaii akamaii 1 year ago
This Wednesday we hope data rules. Give us data 📈
šŸ‘ļø0
akamaii akamaii 1 year ago
Going long for a year 75 target or 50 plus
šŸ‘ļø0
Mt. Blanc Mt. Blanc 1 year ago
So much for my ALT prediction.

The stock slipped to $7 and may be cratering more since it's getting no love.

Maybe ALT is a $5 stock or lower if buyers aren't interested.

mb
šŸ‘ļø0
Mt. Blanc Mt. Blanc 1 year ago
Radar. ALT $11- $12

Getting picked up.

mb
šŸ‘ļø0
Monksdream Monksdream 1 year ago
ALT over $10
Next day settlement begins 5/28 per SEC mandate
šŸ‘ļø0
Monksdream Monksdream 1 year ago
ALT 10Q due 3/27
Next day settlement begins 5/28
šŸ‘ļø0
saigai saigai 1 year ago
patiently waiting.. for sure something in the way of news is right there and it can only be a plus.. i want the buyout.. let say 4 billion.. 80 bucks a share..gl
šŸ‘ļø0
Mark102 Mark102 1 year ago
Buyout? Partnership? In less than 9 trading days we will find out.
šŸ‘ļø0
Mark102 Mark102 1 year ago
BUCKLE UP. going to break 15 soon
šŸ‘ļø0
saigai saigai 1 year ago
a good read
https://www.rcplondon.ac.uk/news/world-obesity-day-let-s-talk-about-drugs
šŸ‘ļø0
saigai saigai 1 year ago
slow and steady is healthy as the data goes as well.. fast weight loss is never good and the deeper dive into the data im sure will find that Alt has a wider profile a safer profile as it relates to muscle loss and bone density. time will tell...in any case the real value here is the undiscovered uses.. wide profile more mkts...long and strong ...
šŸ‘ļø0
Mt. Blanc Mt. Blanc 1 year ago
ALT @ $12?

Interesting

mb
šŸ‘ļø0
saigai saigai 1 year ago
institutional ownership from nasdaq site
https://www.nasdaq.com/market-activity/stocks/alt/institutional-holdings
šŸ‘ļø0
saigai saigai 1 year ago
big volume wrong direction for now
šŸ‘ļø0
saigai saigai 1 year ago
a good read
https://finance.yahoo.com/news/weight-loss-drugs-patients-lose-134837816.html
šŸ‘ļø0
saigai saigai 1 year ago
and a few more...
šŸ‘ļø0
saigai saigai 1 year ago
you wont be able to chase this..you either in before the news or outside looking in.. patience of a saint..
šŸ‘ļø0
saigai saigai 1 year ago
driving me nutz but i wont sell this until !!!
šŸ‘ļø0
murocman murocman 1 year ago
Post from another board relevant to ALT:

GLP-1 drugs will_be supply-constrained for_a_few_years, according to the NVO and LLY webcasts at JPM. All in-house and CMO capacity suitable for manufacturing injected GLP-1 drugs is already in service. Moreover, the eventual uptake of oral GLP-1 drugs will not ease the manufacturing bottleneck as much as people might think because the low bioavailability of the oral agents requires large amounts of API.
šŸ‘ļø0
AGORDON AGORDON 1 year ago
Altimmune, Inc.
(Nasdaq - ALT) $12/share
Market cap = $644M
Cash = $140M
Cash Burn rate = ($76)/Y
Catalysts:
Pemvidutide - Weight loss drug. Peptide based GLP-1/Glucagon dual receptor agonist. Phase 2 results were respectable. At 48 weeks, for 2.4mg (high dose), weight loss of -15.6% (on the low end of the expected 15-20%)., but comparable to Mounjaro. The TRAEs appear to be less than Mounjaro's. The drug did reduce triglycerides.
HepTCell - an immunotherapeutic for Chronic Hepatitis B. In Phase 2 trials. Next read out could be in April, 2024.
šŸ‘ļø0
Mark102 Mark102 1 year ago
I was wrong ALT is attending the JPM Let's get this deal done.
šŸ‘ļø0
saigai saigai 1 year ago
thanks a lot.. im on a new computer.. id rather have oral surgery than learn a new computer
šŸ‘ļø0
Mark102 Mark102 1 year ago
Data is in check Twitter. Weight loss is a 100 billion market. The results on the liver data show a 100 % reduction of fat at the highest dose. That's a 40 billion market.
Now why is ALT not attending the JPM conference this week? Stay tuned
šŸ‘ļø0
saigai saigai 1 year ago
im hanging around bewteen the two potential mkts for their drug its too crazy to even think out loud lets see what the data says.. if its good or really good. all hell will break out
šŸ‘ļø0
Mark102 Mark102 1 year ago
Float is locked, tutes trying to shake few out but this is a done deal IMO
šŸ‘ļø0
saigai saigai 1 year ago
this is a powder keg...
šŸ‘ļø0
saigai saigai 1 year ago
i believe if they wanted to they could have closed a deal by now but they wait till after the new data.. i wonder why.. there is no way for this to go but way up from here..glta
šŸ‘ļø0
Mark102 Mark102 1 year ago
Been Holding since 6. Buyout or partnership is imminent.
šŸ‘ļø0
1hot toddy 1hot toddy 1 year ago
HUGE BUYS NOW 10K BUY $100K BUY $$$$$$$$$$$$$$$$$$
šŸ‘ļø0
Bud-Wiser Bud-Wiser 1 year ago
Nice comeback today -Iā€™m back in
šŸ‘ļø0
1hot toddy 1hot toddy 1 year ago
WOOOOOOOOOOOW 10K AND 9100 SHARE BUYS 2-$100,000 BUYS $$$$$$$$$$$$$$$$$$$$$$$$$$$$$
BABY MONSTER HERE
šŸ‘ļø0
eyeownu eyeownu 1 year ago
got dammmmmmmmmmm. oprah must be buying out the company
šŸ‘ļø0

Your Recent History

NASDAQ
ALT
Altimmune
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub
United States
Company
Business
Popular
Get The App
App Store
Google Play

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN Ltd - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads